GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biogend Therapeutics Co 6733.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

21.00

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 222.3m

FY2017FY2025

Net income

−TWD 84.6m

FY2017FY2025

Free cash flow

−TWD 65.5m

FY2017FY2025

Shareholders' equity

TWD 742.1m

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueTWD 222.3mTWD 167.6mTWD 109.9mTWD 31.4mTWD 9.3mTWD 1.4mTWD 1.5m——
Research and developmentTWD 124.4mTWD 128.7mTWD 171.0mTWD 166.3mTWD 113.3mTWD 94.2mTWD 132.7mTWD 132.0mTWD 135.3m
Operating income−TWD 109.7m−TWD 122.3m−TWD 176.5m−TWD 219.2m−TWD 164.3m−TWD 133.6m−TWD 167.1m−TWD 166.2m−TWD 144.4m
Net income−TWD 84.6m−TWD 116.5m−TWD 156.3m−TWD 184.5m−TWD 138.5m−TWD 145.6m−TWD 162.9m−TWD 167.5m−TWD 129.6m
Diluted earnings per share-0.68-0.93-1.27-1.78-1.32-1.64-1.97-2.72-2.94

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsTWD 815.4mTWD 912.7mTWD 1.05bnTWD 821.8mTWD 1.02bnTWD 725.3mTWD 607.3mTWD 649.2mTWD 437.5m
Cash and short-term investments—————TWD 513.0mTWD 369.8mTWD 440.1mTWD 220.7m
Total liabilitiesTWD 57.7mTWD 66.2mTWD 93.7mTWD 90.6mTWD 80.4mTWD 20.8mTWD 18.0mTWD 17.0mTWD 79.9m
DebtTWD 6.6mTWD 9.4mTWD 13.1mTWD 15.8mTWD 4.4m————
Shareholders' equityTWD 742.1mTWD 817.7mTWD 941.0mTWD 702.9mTWD 887.5mTWD 704.6mTWD 589.3mTWD 632.2mTWD 357.5m
Shares outstanding125m125m123m103m105m89m83m62m44m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−TWD 63.7m−TWD 98.9m−TWD 138.7m−TWD 168.8m−TWD 136.8m—−TWD 147.5m−TWD 144.7m−TWD 150.5m
Capital spending−TWD 1.9m−TWD 650,000−TWD 25.7m−TWD 18.2m−TWD 673,000—−TWD 31.4m−TWD 3.7m—
Free cash flow−TWD 65.5m−TWD 99.6m−TWD 164.4m−TWD 187.0m−TWD 137.5m—−TWD 178.9m−TWD 148.4m−TWD 150.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 59.5mTWD 54.9mTWD 60.5mTWD 61.7mTWD 52.7mTWD 47.5mTWD 50.6mTWD 44.3m
Operating income−TWD 30.9m−TWD 19.8m−TWD 28.6m−TWD 11.3m−TWD 29.2m−TWD 40.7m−TWD 23.6m−TWD 37.5m
Net income−TWD 23.9m−TWD 15.8m−TWD 21.3m−TWD 6.9m−TWD 23.2m−TWD 33.3m−TWD 39.2m−TWD 31.4m
Diluted earnings per share-0.18-0.13-0.17-0.06-0.19-0.27-0.31-0.25
Cash from operations−TWD 10.0m−TWD 13.0m−TWD 9.0m−TWD 12.0m−TWD 8.0m−TWD 32.0m−TWD 13.0m−TWD 21.0m
Capital spending——−TWD 1.0m—————
Free cash flow——−TWD 10.0m—————
Total assetsTWD 1.13bnTWD 1.15bnTWD 815.4m—TWD 845.3mTWD 870.0mTWD 912.7mTWD 941.3m
Shareholders' equityTWD 1.07bnTWD 1.09bnTWD 742.1m—TWD 763.9mTWD 786.6mTWD 817.7mTWD 877.0m

Financial ratios

Data as of 17 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Operating margin-46.5%-76.4%-153.7%-679.9%-1772.7%
Net margin-38.1%-69.5%-142.2%-586.6%-1494.1%
Return on equity-11.4%-14.2%-16.6%-26.2%-15.6%
Return on assets-10.4%-12.8%-14.9%-22.4%-13.5%
Revenue growth32.6%52.5%249.5%239.3%—
Earnings growth-27.4%-25.5%-15.3%33.2%—
Current ratio17.60x21.60x17.32x17.01x29.24x
Equity ratio91.0%89.6%89.6%85.5%86.7%
Interest coverage-685.16x-595.50x-644.89x-2349.49x-9128.28x
R&D as a share of sales56.0%76.8%155.6%528.7%1222.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue91.9%175.8%—
Operating income-20.6%-3.9%—
Net income-22.9%-10.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-56.6-36.0-30.2-12.4-20.2-23.4-15.1
Price to sales21.525.043.072.7302.3——

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.